

**Ad-hoc release pursuant to § 15 Wertpapierhandelsgesetz
(German Securities Trading Act)**

WILEX subsidiary Heidelberg Pharma extends research collaboration with Roche

Munich, Germany, 14 October 2014 – WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) today announced that WILEX subsidiary Heidelberg Pharma and Roche extended the existing 2013 licence agreement to apply the antibody drug conjugate (ADC) technology for the further development of Roche antibodies. The aim is to identify and develop novel Antibody Targeted Amanitin Conjugates (ATACs) based on Heidelberg Pharma's patented technology to couple α -Amanitin to antibodies.

Under the extended licence agreement, Heidelberg Pharma will receive an upfront payment and further regular payments for granting access to its technology and providing research services to Roche, which has the opportunity to exercise options for licences to develop and market selected ATACs. Heidelberg Pharma will manufacture these substances for clinical research and receive undisclosed milestone payments and royalties for each development candidate selected.

Furthermore, exclusive rights to one additional undisclosed tumour target will be granted to Roche. For this target Heidelberg Pharma could potentially receive up to EUR 52 million in upfront and milestone payments for successful clinical development and regulatory approval plus royalties.

+++ End of Ad hoc release +++

About WILEX

WILEX AG is a biopharmaceutical company which has a ready for partnering portfolio of antibody-based diagnostic and therapeutic Phase III product candidates for the detection and targeted treatment of clear cell renal cell carcinoma. Research and development now focus on the operations of its subsidiary Heidelberg Pharma GmbH in Ladenburg, which primarily advances the development of the innovative platform technology for antibody drug conjugates (ADC technology) and offers preclinical services. WILEX is listed at the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / Symbol WL6. More information is available at www.wilex.com.

Contact

WILEX AG

Corporate Communications
Sylvia Wimmer
Tel.: +49 (0)89-41 31 38-29
Email: [investors\[at\]wilex.com](mailto:investors[at]wilex.com)
Grillparzerstr. 10, 81675 Munich

IR/PR support

MC Services AG

Katja Arnold (CIRO)
Executive Director
Tel.: +49-89-210 228-40
E-Mail: [katja.arnold\[at\]mc-services.eu](mailto:katja.arnold[at]mc-services.eu)

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.